Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Phathom Pharmaceuticals (PHAT) Cost of Revenue (2023 - 2025)

Historic Cost of Revenue for Phathom Pharmaceuticals (PHAT) over the last 3 years, with Q3 2025 value amounting to $6.2 million.

  • Phathom Pharmaceuticals' Cost of Revenue rose 16273.34% to $6.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 million, marking a year-over-year increase of 33391.91%. This contributed to the annual value of $8.0 million for FY2024, which is 467425.15% up from last year.
  • Per Phathom Pharmaceuticals' latest filing, its Cost of Revenue stood at $6.2 million for Q3 2025, which was up 16273.34% from $5.0 million recorded in Q2 2025.
  • Phathom Pharmaceuticals' 5-year Cost of Revenue high stood at $6.2 million for Q3 2025, and its period low was $167000.0 during Q4 2023.
  • Its 3-year average for Cost of Revenue is $2.9 million, with a median of $3.0 million in 2024.
  • As far as peak fluctuations go, Phathom Pharmaceuticals' Cost of Revenue surged by 218443.11% in 2024, and later skyrocketed by 16273.34% in 2025.
  • Quarter analysis of 3 years shows Phathom Pharmaceuticals' Cost of Revenue stood at $167000.0 in 2023, then soared by 2184.43% to $3.8 million in 2024, then skyrocketed by 62.25% to $6.2 million in 2025.
  • Its Cost of Revenue was $6.2 million in Q3 2025, compared to $5.0 million in Q2 2025 and $3.7 million in Q1 2025.